ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.
Other News
Caristo Diagnostics Recognized as Quarterfinalist in the Digital Health Awards, Rising Star Category
OXFORD, England, Sept. 3, 2024 /PRNewswire/ — Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected as a quarterfinalist for the prestigious Digital Health Hub Foundation: Digital Health Awards. Caristo was chosen as a…
Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction
Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…
Recor Medical Endorses European Society of Cardiology’s New Guidelines for Management of Hypertension
The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and effectiveness of renal denervation, recommending its consideration as a treatment option to improve uncontrolled hypertension. PALO…
DRAI MARTINI: Artificial Intelligence Beats Human Readers at Arrhythmia Detection
WARSAW, Poland, Sept. 2, 2024 /PRNewswire/ — New research presented at the ESC Congress 2024 reveals that a novel artificial intelligence (AI) algorithm has significantly higher sensitivity than human specialists in detecting heart rhythm disorders on long ECG recordings. The DRAI…
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers with Aficamten
LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%
SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
Hot Line Sessions to Feature Results from Investigational FINEARTS-HF Study in Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Pooled, Exploratory Analysis from Three Pivotal Phase III Trials Exploring Finerenone on Cardio-Kidney Outcomes Detailed data from the Phase III FINEARTS-HF trial that investigated KERENDIA® (finerenone) in patients with heart […]
Renata Medical Receives FDA Approval for the Minima Growth Stent, First-of-its-Kind Device for Treating Aortic Coarctation and Pulmonary Artery Stenosis
August 29, 2024 08:21 AM Eastern Daylight Time NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Renata Medical today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first-of-its-kind Minima Growth Stent that’s specifically tailored for neonates, infants, and young children, but also designed to be re-expanded over the course of their […]
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
August 29, 2024 08:00 AM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions, announced today that the U.S. Food and Drug Administration (FDA) has […]



